Navigation Links
Human Gene Therapy publishes review of randomized clinical trials of gene transfer for heart failure with reduced ejection fraction
Date:4/11/2017

SAN DIEGO, April 11, 2017 /PRNewswire-USNewswire/ -- Renova™ Therapeutics, a biotechnology company developing gene and peptide therapies for cardiovascular and metabolic diseases, today announced its co-founder's online publication of an article in Human Gene Therapy. The article reviews four published clinical trials using gene transfer in patients with heart failure with reduced ejection fraction (HFrEF). The review finds that, while efficacy varied among the clinical trials, gene transfer was not associated with an increased rate of adverse events, supporting further investigations using this treatment method in the HFrEF patient population.

The review, which will be published in the May 2017 print issue of Human Gene Therapy, was co-authored by Dr. H. Kirk Hammond and Dr. William Penny, both Professors of Medicine at the University of California - San Diego and cardiologists at the Veterans Affairs San Diego Healthcare System. Dr. Hammond is a co-founder of Renova Therapeutics and a consultant to the company.

 (PRNewsfoto/Renova Therapeutics)
(PRNewsfoto/Renova Therapeutics)...

The authors reviewed safety and efficacy results of four trials utilizing three gene transfer strategies: intracoronary delivery of adeno-associated virus type 1 encoding sarcoplasmic reticulum Ca2+-ATPase (AAV1.SERCA2a; CUPID 1 and CUPID 2); endocardial injection of a plasmid encoding stromal cell-derived factor-1 (pSDF-;  STOP-HF; and intracoronary delivery of adenovirus-5 encoding human adenylyl cyclase type 6 (Ad5.hAC6).

Results of the AC6 clinical trial indicate that, through a one-time administration, AC6 gene transfer safely increased heart function beyond optimal heart failure therapy. This Phase 2 trial was funded by the National Institutes of Health (NIH), the Gene Therapy Resource Program and Renova Therapeutics, via an NIH public-private partnership.

"With safety results indistinguishable from placebo, we can confidently advance our gene transfer clinical trials," says Dr. Jack W. Reich, CEO and Co-founder of Renova Therapeutics. "The potential therapeutic value of gene transfer in heart failure patients is tremendous."

Renova Therapeutics will conduct a randomized, placebo-controlled, double-blind multicenter Phase 3 trial of intracoronary delivery of Ad5.hAC6 (known as RT-100) to evaluate safety and efficacy. The primary efficacy endpoint will be heart failure hospitalization rate 12 months after randomization. This pivotal trial is expected to commence this year at 60 medical centers in the United States.

About heart failure
Heart failure is a chronic disease characterized by the inability of the heart to pump sufficient blood to meet the body's demands. It is a progressive and fatal chronic condition, and symptoms worsen over time. Heart failure afflicts more than 28 million people globally and is the only cardiovascular disease that is increasing in prevalence. In the United States, it is the most common cause for emergency hospital admissions in patients 65 and older.

About Renova Therapeutics
Renova Therapeutics is developing definitive gene and peptide therapies to restore the health of people suffering from chronic diseases. The first indications the company is pursuing are gene therapy treatments for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company's lead product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with CHF. The company's product pipeline also includes a groundbreaking gene therapy in preclinical stage for sufferers of type 2 diabetes, as well as a peptide infusion therapy for the treatment of acute decompensated heart failure. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit www.renovatherapeutics.com.

References

  • Dr. William F Penny and Dr. H. Kirk Hammond. Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction. Human Gene Therapy. March 2017, ahead of print. doi:10.1089/hum.2016.166.
  • Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–e245.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/human-gene-therapy-publishes-review-of-randomized-clinical-trials-of-gene-transfer-for-heart-failure-with-reduced-ejection-fraction-300437676.html


'/>"/>
SOURCE Renova Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Global Human Embryonic Stem Cell (HESC) Research Report 2014-2017 & 2022 - Research and Markets
2. GigaGen and Trianni Announce License Agreement for Discovery of Fully Human Immuno-Oncology Antibodies
3. Humanized Mouse Model Market Growing at a CAGR of 9.6% During 2016 to 2021
4. Humanized Mouse Model Market Worth 116.0 Million USD by 2021
5. Department of Health and Human Services Appoints Dr. Stephen Rosenfeld SACHRP Chair
6. Regen BioPharma, Inc. Discusses a Recent Important Discovery of NR2F6 in Human Cervical Cancer
7. Allen Institute For Cell Science Releases Gene Edited Human Stem Cell Lines
8. KCAS Bioanalytical and Biomarker Services Now Offers Qualified MSD V-PLEX Human Cytokine 30-plex Assay
9. The Human Vaccines Project and Boehringer Ingelheim Partner To Accelerate the Development of Cancer Vaccines and Immunotherapies
10. iSpecimen and TriCore Reference Laboratories Announce Collaboration to Make Human Biospecimens and Data Available for Research
11. Cell Isolation (Cell Separation) Market to Rise Beyond 17% CAGR to 2021 Led by Human Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a complex biological network, a depiction of a system of linkages and ... Dmitry Korkin, PhD, associate professor of computer science at Worcester Polytechnic Institute (WPI) ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, will ... analytical testing are being attributed to new regulatory requirements for all new drug ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s Medical ... place on 7th and 8th June 2018 in San Francisco, CA. The Summit brings ... well as several distinguished CEOs, board directors and government officials from around the world ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study ... in frozen and fresh in vitro fertilization (IVF) transfer cycles. The ... IVF success. , After comparing the results from the fresh and frozen transfer ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):